Skip to content
Maria Reig MD PhD; ENA 2022 BARCELONA: AUDIO JOURNAL OF ONCOLOGY: ”New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma

Maria Reig MD PhD; ENA 2022 BARCELONA: AUDIO JOURNAL OF ONCOLOGY: ”New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma

Get the podcast

New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma Interview with: Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona a

The Audio Journal of Oncology

New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma

Interview with:

Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona at Barcelona University, Spain.

BARCELONA, Spain—A phase one study of new drug targeting the monopolar spindle 1 enzyme was found to be safe—with reversible neutropenia as the commonest side effect—and to have clinical activity in patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). Maria Reig MD PhD announced the study findings at the 2022 European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics.

She gave the Audio Journal of Oncology’s Peter Goodwin more details of this new type of treatment, that she says works in a very different way from the current options for treating liver cancer.

Tags

ENA 2022HCChepatocellular carcinomaliver cancerMPS1 inhibitorNew kinase inhibitor for HCC

Next in AACR

All 45 interviews

Interview 34 of 45

BRCA-deficient cancers respond to combination of two experimental drugs

BRCA-deficient cancers respond to combination of two experimental drugs

WASHINGTON DC—Doctors taking the unusual step of combining two experimental drugs to treat cancers in patients who have mutated BRCA — the gene conferring susceptibility to breast, ovarian and some ot

24 April 2013

Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

10 Nov 2026
10 min
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min
Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca

21 May 2026
11 min